222 related articles for article (PubMed ID: 16704922)
1. Antifungals and renal safety--getting the balance right.
Saliba F
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():21-4. PubMed ID: 16704922
[TBL] [Abstract][Full Text] [Related]
2. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
3. The experience is CLEAR.
Chandrasekar P
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248
[TBL] [Abstract][Full Text] [Related]
4. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections.
Drew R
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():36-44. PubMed ID: 16713192
[TBL] [Abstract][Full Text] [Related]
5. Controlled trials of amphotericin B lipid complex and other lipid-associated formulations.
Winston DJ; Schiller GJ
Clin Infect Dis; 2000 Jan; 30(1):236-7. PubMed ID: 10619780
[No Abstract] [Full Text] [Related]
6. Amphotericin B lipid complex.
Rapp RP; Gubbins PO; Evans ME
Ann Pharmacother; 1997 Oct; 31(10):1174-86. PubMed ID: 9337444
[TBL] [Abstract][Full Text] [Related]
7. ABELCET treatment.
Boyle JA; Swenson CE
J Clin Pharmacol; 1999 Apr; 39(4):427-8. PubMed ID: 10197303
[No Abstract] [Full Text] [Related]
8. Mortality rates in comparative trials of formulations of amphotericin B.
Frothingham R
Clin Infect Dis; 2001 Aug; 33(4):582-3. PubMed ID: 11462201
[No Abstract] [Full Text] [Related]
9. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex.
Perfect JR
Clin Infect Dis; 2005 May; 40 Suppl 6():S401-8. PubMed ID: 15809926
[TBL] [Abstract][Full Text] [Related]
10. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
11. Use of an amphotericin B lipid complex for treatment of blastomycosis in dogs.
Krawiec DR; McKiernan BC; Twardock AR; Swenson CE; Itkin RJ; Johnson LR; Kurowsky LK; Marks CA
J Am Vet Med Assoc; 1996 Dec; 209(12):2073-5. PubMed ID: 8960189
[TBL] [Abstract][Full Text] [Related]
12. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B.
Barcia JP
Pharmacotherapy; 1998; 18(4):874-6. PubMed ID: 9692667
[TBL] [Abstract][Full Text] [Related]
13. Study of renal safety in amphotericin B lipid complex-treated patients.
Alexander BD; Wingard JR
Clin Infect Dis; 2005 May; 40 Suppl 6():S414-21. PubMed ID: 15809928
[TBL] [Abstract][Full Text] [Related]
14. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
Zhang Z; Diener RM; Lipman JM
Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
[TBL] [Abstract][Full Text] [Related]
15. Lipid-based antifungal agents.
Arikan S
Cell Mol Biol Lett; 2002; 7(2):220-1. PubMed ID: 12097922
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections.
Wiley JM; Seibel NL; Walsh TJ
Pediatr Infect Dis J; 2005 Feb; 24(2):167-74. PubMed ID: 15702047
[TBL] [Abstract][Full Text] [Related]
17. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis.
Baddour LM; Perfect JR; Ostrosky-Zeichner L
Clin Infect Dis; 2005 May; 40 Suppl 6():S409-13. PubMed ID: 15809927
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry.
Pappas PG
Clin Infect Dis; 2005 May; 40 Suppl 6():S379-83. PubMed ID: 15809923
[No Abstract] [Full Text] [Related]
19. Lipid-based amphotericin in pulmonary zygomycosis: safety and efficacy of high exposure in a renal allograft recipient.
Crompton JA; Alexander D; Somerville T; Shihab FS
Transpl Infect Dis; 2004 Dec; 6(4):183-7. PubMed ID: 15762937
[TBL] [Abstract][Full Text] [Related]
20. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
Garbino J; Markham L; Matulionyte R; Rives V; Lew D
Scand J Infect Dis; 2006; 38(2):110-3. PubMed ID: 16449001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]